High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: A retrospective analysis of a clinical cohort

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Gerver, Sarah M ^a,c   Chadborn, Tim R ^b   Ibrahim, Fowzia ^a   Vatsa, Bela ^b   Delpech, Valerie C ^b   Easterbrook, Philippa J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; ETHNICITY; FEMALE; FOLLOW UP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; VIRUS LOAD; AMBULATORY CARE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; STATISTICS;

ADULT; AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; LONDON; LOST TO FOLLOW-UP; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77957119595     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-29     Document Type: Article

References (34)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Antiretroviral Therapy Cohort Collaboration, Lancet 2008 372 293 299 10.1016/S0140-6736(08)61113-7 18657708
2. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. C Smit R Geskus S Walker C Sabin R Coutinho K Porter M Prins C Collaboration, AIDS 2006 20 741 749 10.1097/01.aids.0000216375. 99560.a2 16514305
3. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. JE Kaplan D Hanson MS Dworkin T Frederick J Bertolli ML Lindegren S Holmberg JL Jones, Clinical Infectious Diseases 2000 30 Suppl 1 5 S14 10.1086/313843 10770911
4. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. S Grinspoon A Carr, New England Journal of Medicine 2005 352 48 62 10.1056/NEJMra041811 15635112
5. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. S Hetherington S McGuirk G Powell A Cutrell O Naderer B Spreen S Lafon G Pearce H Steel, Clinical Therapeutics 2001 23 1603 1614 10.1016/S0149-2918(01)80132-6 11726000
6. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. M Nunez, Journal of Hepatology 2006 44 132 S139 10.1016/j.jhep.2005.11.027 16364487
7. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier MM Wagener N Singh, Annals of Internal Medicine 2000 133 21 30 10877736
8. Adherence to triple therapy and viral load response. S Low-Beer B Yip MV O'Shaughnessy RS Hogg JS Montaner, Journal of Acquired Immune Deficiency Syndromes: JAIDS 2000 23 360 361
9. Understanding transmitted HIV resistance through the experience in the USA. B Taiwo, International Journal of Infectious Diseases 2009 13 552 559 10.1016/j.ijid.2008.10.008 19136289
10. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. FJ Palella RK Baker AC Moorman JS Chmiel KC Wood JT Brooks SD Holmberg Investigators HIVOS, JAIDS Journal of Acquired Immune Deficiency Syndromes September 2006 43 27 34 10.1097/01.qai.0000233310.90484.16
11. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? A Jutte A Schwenk C Franzen K Romer F Diet V Diehl G Fatkenheuer B Salzberger, AIDS 1999 13 1796 1797 10.1097/00002030-199909100- 00034 10509592
12. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. D. A. D. Study Group CA Sabin SW Worm R Weber P Reiss W El-Sadr F Dabis S De Wit M Law A D'Arminio Monforte N Friis-Møller O Kirk C Pradier I Weller AN Phillips JD Lundgren, Lancet 2008 371 1417 1426 10.1016/S0140-6736(08)60423-7 18387667
13. Standards for HIV Clinical Care. British HIV Association, 2007
14. Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. S Perez-Hoyos MA Rodriguez-Arenas M Garcia de la Hera JA Iribarren S Moreno P Viciana A Pena JL Gomez Sirvent M Saumoy J Lacruz S Padilla JA Oteo R Asencio J del Amo, Journal of Women's Health 2007 16 1052 1061 10.1089/jwh.2007.0437 17903082
15. Effect of early versus deferred antiretroviral therapy for HIV on survival. MM Kitahata SJ Gange AG Abraham B Merriman MS Saag AC Justice RS Hogg SG Deeks JJ Eron JT Brooks SB Rourke MJ Gill RJ Bosch JN Martin MB Klein LP Jacobsen B Rodriguez TR Sterling GD Kirk S Napravnik AR Rachlis LM Clazavara MA Hoberg MJ Silverberg KA Gebo JJ Goedert CA Benson AC Collier SE Van Rompaey HM Crane RG McKaig B Lau AM Freemand RD Moore NA-ACCORD Investigators, New England Journal of Medicine 2009 360 1815 1826 10.1056/NEJMoa0807252 19339714
16. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. JK Yu SC Chen KY Wang CS Chang SD Makombe EJ Schouten AD Harries, Bulletin of the World Health Organization 2007 85 550 554 10.2471/BLT.06.037739 17768504
17. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. H Karcher A Omondi J Odera A Kunz G Harms, Tropical Medicine & International Health 2007 12 687 694
18. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. RP Dalal C Macphail M Mqhayi J Wing C Feldman MF Chersich WD Venter, Journal of Acquired Immune Deficiency Syndromes: JAIDS 2008 47 101 107 10.1097/QAI.0b013e31815b833a
19. Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. JP Ioannidis TE Taha N Kumwenda R Broadhead L Mtimavalye P Miotti F Yellin DG Contopoulos-Ioannidis RJ Biggar, International Journal of Epidemiology 1999 28 769 775 10.1093/ije/28.4.769 10480709
20. Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. S Rosen MP Fox CJ Gill, PLoS Medicine 2007 4 298 10.1371/journal.pmed.0040298 17941716
21. Predictors identified for losses to follow-up among HIV-seropositive patients. E Lanoy M Mary-Krause P Tattevin R Dray-Spira C Duvivier P Fischer Y Obadia F Lert D Costagliola Clinical Epidemiology Group of French Hospital Database on HIVI, Journal of Clinical Epidemiology 2006 59 829 835 10.1016/j.jclinepi.2005.11.024 16828676
22. Retention challenges for a community-based HIV primary care clinic and implications for intervention. S Coleman U Boehmer F Kanaya C Grasso J Tan J Bradford, AIDS Patient Care STDS 2007 21 691 701 10.1089/apc.2006.0205 17919096
23. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. B Lebouche Y Yazdanpanah Y Gerard D Sissoko F Ajana I Alcaraz P Boitte B Cadore Y Mouton, HIV Medicine 2006 7 140 145 10.1111/j.1468-1293.2006.00357.x 16494627
24. Loss to follow-up in an international, multicentre observational study. A Mocroft O Kirk P Aldins A Chies A Blaxhult N Chentsova N Vetter F Dabis J Gatell LD Lundgren group ftEs, HIV Medicine 2008 9 261 269 10.1111/j.1468-1293. 2008.00557.x 18400074
25. A national HIV community cohort: design, baseline, and follow-up of the AmFAR Observational Database. American Foundation for AIDS Research Community-Based Clinical Trials Network. CJ Cohen MK Iwane JB Palensky DL Levin KJ Meagher KR Frost KH Mayer, Journal of Clinical Epidemiology 1998 51 779 793 10.1016/S0895-4356(98)00043-2 9731927
26. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. C Arici D Ripamonti F Maggiolo M Rizzi MG Finazzi P Pezzotti F Suter, HIV Clinical Trials 2002 3 52 57 10.1310/2XAK-VBT8-9NU9-6VAK 11819186
27. Factors affecting attrition in a longitudinal study of patients with AIDS. DM Brown JE Thorne GL Foster JL Duncan LM Brune A Munana CL Meinert DA Jabs, AIDS Care 2006 18 821 829 10.1080/09540120500466747 16971294
28. Retention of Women Enrolled in a Prospective Study of Human Immunodeficiency Virus Infection: Impact of Race, Unstable Housing, and Use of Human Immunodeficiency Virus Therapy. NA Hessol M Schneider RM Greenblatt M Bacon Y Barranday S Holman E Robison C Williams M Cohen K Weber, American Journal of Epidemiology 2001 154 563 573 10.1093/aje/154.6.563 11549562
29. The Multicenter AIDS Cohort Study: Retention after 9 1/2 Years. J Dudley S Jin D Hoover S Metz R Thackeray J Chmiel, American Journal of Epidemiology 1995 142 323 330 7631636
30. The epidemiology of HIV in South East London 1995-2005. South East London Health Protection Unit, London 2007
31. 'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. JY Mortimer JA Salathiel, Communicable Disease Report CDR Review 1995 5 183 186 8541940
32. Who starts antiretroviral therapy in Durban, South Africa?.not everyone who should. IV Bassett S Regan S Chetty J Giddy LM Uhler H Holst D Ross JN Katz RP Walensky KA Freedberg E Losina, AIDS 2010 24 Suppl 1 37 S44 10.1097/01.aids.0000366081.91192.1c 20023438
33. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. P Braitstein A Boulle D Nash MW Brinkhof F Dabis C Laurent M Schechter SH Tuboi E Sprinz P Miotti M Hosseinpour M May M Egger DR Bangsberg L Low The Antiretrovial Therapy In Lower Income Countries (ART-LINC) Study Group, Journal of Women's Health 2008 17 47 55 10.1089/jwh.2007.0353 18240981
34. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. AS Muula TJ Ngulube S Siziya CM Makupe E Umar HW Prozesky CS Wiysonge RH Mataya, BMC Public Health 2007 7 63 10.1186/1471-2458-7-63 17459154